Immunohistochemical examination of mesothelin expression in surgically resected tumor specimens is clinically useful for assessing the prognosis and for deciding on the necessity of additional treatment following surgical procedures in patients with IPMN. This evidence concerns the gene MSLN and pancreatic intraductal papillary-mucinous neoplasm.